InflaRx NV Stock Price - IFRX

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
InflaRx NV IFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.19 -5.83% 3.07 3.29 3.05 3.26 3.26 12:52:18
Bid Price Ask Price Spread Spread % News
3.06 3.08 0.02 0.65% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,810 544,461 $ 3.13 $ 1,705,275 858,694 2.17 - 53.10
Last Trade Time Type Quantity Stock Price Currency
12:52:34 200 $ 3.07 USD

InflaRx NV Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 80.14M 26.11M $ -29.82M -1.37 - 26.11M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

InflaRx NV News

Loading Messages....

Latest IFRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IFRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.473.70013.043.45846,142-0.40-11.53%
1 Month2.603.70012.263.101,003,5250.4718.08%
3 Months3.033.882.172.87594,9580.041.32%
6 Months3.353.992.173.05976,092-0.28-8.36%
1 Year29.0853.102.177.31716,047-26.01-89.44%
3 Years15.1953.102.178.71372,228-12.12-79.79%
5 Years15.1953.102.178.71372,228-12.12-79.79%

InflaRx NV Description

InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Your Recent History
InflaRx NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.